TRANSFORM PACK INTERNATIONAL INC Form 8-K/A October 02, 2003

> SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> > FORM 8-K/A CURRENT REPORT

(Amendment 1)

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 28, 2003

Commission File No. 000-31727

TRANSFORM PACK INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter)

Minnesota (State or Other Jurisdiction of
Incorporation or Organization)(IRS Employer
Identification No.)

41-1886254

12230 Forest Hill Boulevard Suite 157 Wellington, Florida 33414 (Address of principal executive offices)

> (561) 227-1597 (Issuer's telephone number)

929 Cedar Cove Road, Wellington, Florida 33414 (Former name or former address, if changed since last report.)

Transform Pack International, Inc., a Minnesota corporation, is filing this amendment to its Form 8-K dated May 28, 2003 in order to provide Item 7. (a) Financial Statements of Business Acquired

ITEM 7. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

The audited financial statements of Quantum HIPAA Consulting Group, Inc. for the fiscal years ended October 31, 2002 and 2001

The unaudited financial statements of Quantum HIPAA Consulting Group, Inc. for the six months ended April 30, 2003 and 2002, and for the period July 24, 2001 (inception) to April 30, 2003.

(b) Pro Forma Financial Information.

The pro forma balance sheets at April 30, 2003 and October 31, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Transform Pack International, Inc.

Date: October 2, 2003

/s/ Noel J. Guillama, President

2

TABLE OF CONTENTS

Independent Auditor's Report

Financial Statements:

Balance Sheets as of October 31, 2002 and 2001 and unaudited as of April 30, 2003

Statements of Operations for the year ended October 31, 2002, for the period July 24, 2001 (inception) to October 31, 2001, unaudited for the six months ended April 30, 2003 and 2002, and unaudited for the period July 24, 2001 (inception) to April 30, 2003.

Statements of Changes in Deficiency in Assets for the year ended October 31, 2002, the for the period July 24, 2001 to October 31, 2001, and unaudited for the six months ended April 30, 2003

Statements of Cash Flow for the year ended October 31, 2002, for the period July 24, 2001 (inception) to October 31, 2001, unaudited for the six

4

5

6

7

months ended April 30, 2003 and 2002, and unaudited for the period July 24, 2001 (inception) to October 31, 2003 $\,$

Notes to Financial Statements

9

8

3

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors and Stockholders

Quantum HIPAA Consulting Group, Inc.

We have audited the accompanying balance sheets of Quantum HIPAA Consulting Group, Inc. as of October 31, 2002 and 2001, and the related statements of operations, changes in deficiency in assets and cash flows for the year ended October 31, 2002 and for the period July 24, 2001 (inception) to October 31, 2001. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Quantum HIPAA Consulting Group, Inc. as of October 31, 2002 and 2001, and the results of its operations and its cash flows for the year ended October 31, 2002 and for the period July 24, 2001 to October 31, 2001 in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses and had negative cash flows from operations which raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in the Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

3

/s/ Daszkal Bolton LLP

Boca Raton, Florida

September 9, 2003

4

Quantum HIPAA Consulting Group, Inc. (A Development Stage Enterprise) Balance Sheet

	•	October 31, 2001	
			(unaudited)
ASSETS			
Current assets: Cash	\$ –	\$ 555	Ş –
Total current assets		555	
Property and equipment, net of accumulated depreciation of \$1,657, \$414 and \$2,279 Other assets Total assets	1,820	3,315 1,820 \$ 5,690	\$ 1,450
LIABILITIES AND SHAREHOLDERS' DEFICIT			
Current liabilities: Accounts payable and accrued liabilities Loan payable - shareholder		\$ 25,006 88,260	
Total current liabilities	197,868	113,266	254,857

Commitments and contingencies

Deficiency in assets		(193,9	976) (1			(253,407	')	
Total liabilities and de assets	-		92 \$ ==== ====	•) \$	1,450		
See acco	ompanying notes to	financi	al stateme	ents.				
	5							
Qı	aantum HIPAA Consu (A Development St Statement of	age Ente	erprise)					
	T		the period				the second second	т
	For the year ended October 31, 2002	(inc	eption) to	o			onth ended April 30, 2002	(1
							(unaudited)	
Expenses Representing Net Loss	\$ (86,400)	\$ ======	(127,5	76) \$ === ==	(59	9,431) ======	\$ (48,134)) \$ = ==
Basic and diluted loss per common share	\$ (0.004)) \$ = ==
Weighted average number of common shares outstanding	20,000,000		20,000,00)0 === ==	20,000),000 ======	20,000,000	

See accompanying notes to financial statements.

6

Qunatum HIPAA Consulting Group, Inc. (A Development Stage Enterprise) Statement of Changes in Deficiency in Assets

	par value \$. 90,000,000	n Stock 001 per share authorized	Additional	During		
		Amount		1		
Balance 7/24/01 (inception)	-	\$ –	\$ –	\$ –	\$ –	
Sale of common stock Net Loss	20,000,000	\$ 20,000	\$ –	\$ (127,576)		
Balance 10/31/01	20,000,000	\$ 20,000	\$ –	\$ (127,576)	\$(107,576)	
Net Loss				\$ (86,400)	\$ (86,400)	
Balance at 10/31/02	20,000,000	\$ 20,000	\$	\$ (213,976)	\$(193,976)	
Unaudited:						
Net Loss				\$ (59,431)	(59,431)	
Balance at 4/30/03	20,000,000	20,000	\$ – ======	\$ (273,407)	\$(253,407)	

See accompanying notes to financial statements.

7

Quantum HIPAA Consulting Group, Inc. (A Development Stage Enterprise) Statements of Cash Flow

	For the period			
	from July 24, 2001	Six months	Six months	July 24, 200
Year ended	(inception to	ended	ended	(inception)
October 31,	October 31,	April 30	April 30	April 30
2002	2001	2003	2002	2003
		(unaudited)	(unaudited)	(unaudited)

OPERATING ACTIVITIES Net (loss)	\$ (86,400)	Ş	(127,576)	\$ (59,431)	\$ (48,134)	\$	(273,40
Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization	d 1,243		414	622	622		2,27
Changes in operating assets and liabilities: (Increase) decrease in other assets Increase (decrease) in			(1,820)	1,820			
accounts payable and accrued liabilities	(6,218)		25,007				71 , 24
Total adjustments			23,601	54,899	(15,906)		73,52
Net cash used in operating activities					(64,040)		(199,88
INVESTING ACTIVITIES Purchase of property and equipment Investment in related companies			(3,730)				(3,73
Net cash (used in) investing activities			(3,730)				(3,73
FINANCING ACTIVITIES Proceeds from loan payable- shareholder Proceeds from issuance of common stock	90 , 820		88,260 20,000	4,532	63 , 485		183,61 20,00
Net cash provided by financing activities	90,820		108,260	4,532	63,485		203,61
Net increase (decrease) in cash	(555)		555	0	(555)		(
Cash at beginning of period	555		-	-	555		
Cash at end of period	\$ (0)	\$ =====	555	\$0 ======	\$ (0) ======	\$ ===	(
Supplemental disclosures of cash flow information:							
Cash paid during the period for interest	\$ –	\$	-	\$ –	\$ –	Ş	

See accompanying notes to financial statements.

8

QUANTUM HIPAA CONSULTING GROUP, INC. (A DEVELOPMENT STAGE ENTERPRISE) NOTES TO FINANCIAL STATEMENTS

NOTE 1: DESCRIPTION OF COMPANY

Quantum HIPAA Consulting Group, Inc. was incorporated on July 24, 2001. The Company is a development stage enterprise which was formed to provide medical practice and HIPAA compliance consulting services to the health care industry.

The accompanying financial statements reflect ongoing losses, negative cash flows from operating activities, negative working capital and shareholders' deficit.

The Company has no revenues to date. Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company's business plan will be successfully executed. The Company's ability to execute its business model will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Nor can any assurance be made that the Company will generate substantial revenues or that the business operations will prove to be profitable. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cash Equivalents

The Company considers all highly liquid debt instruments with original maturities of three months or less to be cash equivalents. For the six months ended July 31, 2003 and 2002, there were no cash equivalents.

Property and Equipment

Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three to five years.

Research and Development Costs

Research and development costs are charged to expense when incurred.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and

the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates and the differences could be material.

9

QUANTUM HIPAA CONSULTING GROUP, INC. (A DEVELOPMENT STAGE ENTERPRISE) NOTES TO FINANCIAL STATEMENTS

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Income Taxes

The Company has not recognized any benefit of start up cost or net operating loss carry forwards, totaling approximately \$255,000, in the accompanying financial statements in accordance with the provisions of SFAS No. 109, as the realization of this deferred tax benefit is not likely. A 100% valuation allowance has been recognized to offset the entire effect of the Company's net deferred tax asset. The net operating losses will expire in 2021 and 2022.

Recent Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards (" SFAS ') No. 143 which requires entities to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred and a corresponding increase in the carrying amount of the related long-lived asset. Subsequently, the asset retirement cost should be allocated to expense using a systematic and rational method over its useful life. SFAS No. 143 is effective for fiscal years beginning after June 15, 2002. Adoption of SFAS No. 143 did not have a material impact on the Company's financial statements.

In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities. This statement addresses accounting and reporting for costs associated with exit or disposal activities and nullifies emerging issues Task Force Issue No. 94-3. The statement is effective for exit or disposal costs initiated after December 31, 2002, with early application encouraged. The Company adopted SFAS No. 146 effective January 1, 2003, which did not have a material impact on the Company's financial statements.

In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure-an amendment of FASB Statement No. 123. This statement provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. Adoption of SFAS No. 148 did not have a material impact on the Company's financial statements.

10

QUANTUM HIPAA CONSULTING GROUP, INC. (A DEVELOPMENT STAGE ENTERPRISE) NOTES TO FINANCIAL STATEMENTS

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

In May 2003, the FASB issued SFAS No. 150, "Accounting For Certain Financial Instruments with Characteristics of both Liabilities and Equity". SFAS No. 150 changes the accounting for certain financial instruments with characteristics of both liabilities and equity that, under previous pronouncements, issuers could account for as equity. The new accounting guidance contained in SFAS No. 150 requires that those instruments be classified as liabilities in the balance sheet. SFAS No. 150 affects the issuer's accounting for three types of freestanding financial instruments. One type is mandatory redeemable shares, which the issuing company is obligated to buy back in exchange for cash or other assets. A second type includes put options and forward purchase contracts, which involve instruments that do or may require the issuer to buy back some of its shares in exchange for cash or other assets. The third type of instruments that are liabilities under this Statement is obligations that can be settled with shares, the monetary value of which is fixed, tied solely or predominantly to a variable such as a market index, or varies inversely with the value of the issuers' shares. SFAS No. 150 does not apply to features embedded in a financial instrument that is not a derivative in its entirety. Most of the provisions of SFAS No. 150 are consistent with the existing definition of liabilities in FASB Concepts Statement No. 6, "Elements of Financial Statements". The remaining provisions of this Statement are consistent with the FASB's proposal to revise that definition to encompass certain obligations that a reporting entity can or must settle by issuing its own shares. This Statement shall be effective for financial instruments entered into or modified after May 31, 2003 and otherwise shall be effective at the beginning of the first interim period beginning after June 15, 2003, except for mandatory redeemable financial instruments of a non-public entity, as to which the effective date is for fiscal periods beginning after December 15, 2003. The Company is currently assessing the impact of SFAS No. 150, which is not expected to have a material impact on the Company's financial statements.

Interim Financial Information for the Six Month Period Ended April 30, 2003 and 2002 $\,$

The information presented as of April 30, 2003 and 2002 has not been audited. In the opinion of management, the unaudited interim financial statements include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the Company's financial position as of April 30, 2003 and 2002, and the results of its operations and its cash flows for the six months ended April 30, 2003 and 2002, and the stockholders' deficit for the six months ended April 30, 2003. The results of operations for the six months period ended April 30, 2003 are not necessarily indicative of the results for the full year.

NOTE 3: COMMITMENTS

As of October 31, 2002, the Company had commitments under operating leases for premises, maturing December 31, 2002. Rent expense for the year ended October 31, 2002 was \$18,447.

NOTE 4: RELATED PARTY TRANSACTIONS

From inception, July 24, 2001 through October 31, 2002, the sole shareholder has advanced to the Company \$179,080, which is non-interest bearing. (See Note 5)

11

QUANTUM HIPAA CONSULTING GROUP, INC. (A DEVELOPMENT STAGE ENTERPRISE)

NOTES TO FINANCIAL STATEMENTS

NOTE 5: SUBSEQUENT EVENTS

On November 1, 2002, the Company entered into an agreement with a shareholder to purchase certain intellectual property integral to the Company's business. In exchange, the company issued a three (3) year installment note for \$179,080 with an interest rate of eighteen percent (18%) per annum. The price of the sale was equal to the cost the shareholder incurred to develop the property purchased. The note is payable monthly starting January 2003. The Company is in technical default as no payments have been made on the note. The Company is accruing interest, at 18% per annum, monthly on the unpaid principal balance and has classified the note as current as per the agreement.

On November 2, 2002 the Company signed a demand note, with an interest rate of eighteen percent (18%) per annum, for the expenses a shareholder paid on behalf of the Company subsequent to the sale of the intellectual property. The note balance as of April 30, 2003 was \$4,532.

Effective May 28, 2003, the Company consummated a merger pursuant to a merger agreement with Transform Pack International, Inc. The Transform Pack International, Inc. completed the merger by issuing 27,000,000 million shares of Common Stock, in exchange for all the issued and outstanding shares of the Company. For accounting purposes, the acquisition will be treated as a recapitalization of the Company. The value of the net assets of the Company after the acquisition was completed is the same as their historic book value.

In July 2003, the Company purchased a 20% interest Renaissance Health Systems, Inc. for \$5,000 from a shareholder of the Company. Renaissance Health Systems is a development stage enterprise in the health care business. Additionally, the Company purchased a 20% interest in Quantum Medical Technologies, Inc. for \$5,000 from a shareholder of the Company. Quantum Medical Technologies, Inc. is a development stage enterprise in the medical technologies business.

12

Pro Forma Financial Information

Transform Pack International, Inc. and Quantum HIPAA Consulting Group, Inc. Introduction to Pro Forma Balance Sheet (Unaudited)

On May 28, 2003 a majority of the shareholders of Transform Pack International, Inc. approved an Agreement and Plan of Exchange between Transform Pack International, Inc. and Quantum HIPAA Consulting Group, Inc. whereby Transform Pack International, Inc. issued 27,000,000 shares of its Common Stock in exchange for all of the outstanding common stock of Quantum HIPAA Consulting Group, Inc.

The following Pro Forma Combined Balance Sheets of the Registrant are reflective of the year end change to October 31st, as filed on 8-K dated August 29, 2003 and have been prepared by management of the Registrant based upon the balance

sheets of the Registrant as of August 31, 2002 and February 28, 2003 and of Quantum HIPAA Consulting Group, Inc. as of October 31, 2002 and April 30, 2003. For accounting purposes, the acquisition has been treated as an acquisition of Transform Pack International, Inc. by Quantum HIPAA Consulting Group, Inc. and as a recapitalization of Quantum HIPAA Consulting Inc. The pro forma balance sheet gives effect to the transaction as a public shell merger and the assumptions and adjustments in the accompanying notes to pro forma combined balance sheets. The pro forma combined balance sheet as of October 31, 2002 gives effect to the transaction as if it had occurred as of August 31, 2002. The pro forma combined balance sheet as of April 30, 2003 gives effect to the proposed transaction as if it had occurred as of February 28, 2003.

The pro forma adjustments are based upon available information and certain assumptions that management believes are reasonable. The pro forma combined balance sheets do not purport to represent what the combined companies' financial position would actually have been had the proposed transaction occurred on such date or as of the beginning of the period indicated, or to project the combined companies' financial position for any future period.

13

Transform Pack International, Inc. and Quantum HIPAA Consulting Group, Inc. Pro Forma Condensed Combined Balance Sheet October 31, 2002 (Unaudited)

ASSETS

	Histo	rical				
	31, 2002			Pro Forma Adjustments		
CURRENT ASSETS						
Cash			\$ –		\$ -	
Inventory	-	76,363	76,363	(76,363)	-	
Prepaid expenses and other						
assets				\$ (4,597)		
Accounts recievable	-	127,694	127,694	(127,694)	-	
Total Current Assets		208,654	208,654	(208,654)		
PROPERTY & EQUIPMENT - NET	2,072	381 , 553	383,625	(381,553)	2,072	
OTHER ASSETS						
Other assets Investment in affiliate	1,820		1,820 2,000	(2,000)	1,820	
Total Other Assets	1,820	2,000	3,820	(2,000)	1,820	
TOTAL ASSETS	\$ 3,892	\$ 592,207	· ·	\$ (592,207)	\$ 3,892	

LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES: Cash overdraft Accounts payable		\$ 429,221 445,516		\$ (429,221) (324,664)		_ 139,640
Current-portion - LT debt Current-portion - redeemable		66,951				_
preferred shares		120,000	120,000	(120,000)		-
Loan payable	179 , 080		179,080			179 , 080
	-	-	-	-		-
Total Current						
Liabilities	197,868	1,061,688	1,259,556	(940,836)		318 , 720
Long-term debt	_	806,323	806,323	(806,323)		_
Due to shareholder	_	221,077	221,077	(221,077)		-
Total Long-term						
Liabilities	_	1,027,400	1,027,400	(1,027,400)		_
Shareholders' Equity (Deficit):						
Common stock	20,000	2,080,812	2,100,812	(1,972,376)	(a)	128 , 436
Additional paid in capital	_		-	(229,288)	(a)	(229 , 288
Retained Earnings	(213,976)	(3,577,693)	(3,791,669)	3,577,693		(213,976
Total Shareholders' Equity						
(Deficit)	(193,976)	(1,496,881)	(1,690,857)	1,376,029		(314,828
TOTAL LIABILITIES &						
SHAREHOLDERS' EQUITY (DEFICIT)	\$ 3,892	, , ,	\$ 596,099 ========	\$ (592,207)	\$ ==	3,892

See notes to pro forma condensed balance sheets.

14

Transform Pack International, Inc. and Quantum HIPAA Consulting Group, Inc. Pro Forma Condensed Combined Balance Sheet April 30, 2003 (Unaudited)

ASSETS

	Historical								
	4/30/2003 Quantum		/28/2003 cansform			Pro Forma Adjustments		Pro Forma Combined	
CURRENT ASSETS Cash		ć	50,261	ć	50 261	ċ	(50,261)	Ċ	
Lash Inventory Prepaid expenses and other		Ş	40,347	Ş	50,261 40,347	Ş	(40,347)	Ş	_

assets	_	922	922	(922)		-
Total Current Assets		91,530	91 , 530	(91,530)		
PROPERTY & EQUIPMENT - NET	1,450	350 , 787	352,237	(350,787)		1,450
OTHER ASSETS Seccurity deposits	_		_	_		_
Investment in affiliate	-	2,000	2,000	(2,000)		-
Total Other Assets	-	2,000	2,000	(2,000)		
TOTAL ASSETS	\$ 1,450	\$ 444,317	\$ 445,767	\$ (444,317)	\$	1,450
LIARIIITI	LEG C STOCKHO	DLDERS' EQUITY				
CURRENT LIABILITIES:	ES & SIUCNIO	TDEK2. EÃOIII	(DELICII)			
	Ś –	\$ 426,004	\$ 426.004	\$ (426,004)	Ś	_
Accounts payable Current-portion - LT debt	/1/245	66,951	66,951	(66,951)	(,	±,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Current-portion - redeemable		00,001	00,001	(00,001)		
preferred shares		566.250	566.250	(566,250)		-
Loan payable	183,612					183 , 612
Total Current						
Liabilities	254,857	1,423,421	1,678,278	(1,302,569)		375,709
Long-term debt	_	406.760	406,760	(406,760)		_
Due to shareholder	-	231,077	231,077	(231,077)		
Total Long-term Liabilities		 637 , 837	 637 , 837	(637,837)	_	
Shareholders' Equity						
(Deficit): Common stock	20,000	2,130,820	2,150,820	(2,022,384)		
Additional paid in capital Retained Earnings	(273,407)	(3,747,761)	- (4,021,168)	(229,288) 3,747,761		(229,288 (273,407
Total Shareholders'Equity						
(Deficit)	(253,407)			1,496,089		(374,259
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY						
	¢ 1 4 5 0	¢ 444 017		\$ (444,317)	ć	1,450

See notes to pro forma condensed balance sheets.

15

Notes to Pro Forma Condensed Balance Sheets (Unaudited)

The pro forma balance sheet at April 30, 2003 is based on the period ended

February 28, 2003 for the registrant and April 30, 2003 for Quantum HIPAA Consulting Group, Inc. The pro forma balance sheet gives effect to the share exchange as if it had occurred on February 28, 2003. The pro forma balance sheet at October 31, 2002 is based on the period ended August 31, 2002 for the registrant and October 31, 2002 for Quantum HIPAA Consulting Group, Inc. The pro forma balance sheet gives effect to the share exchange as if it had occurred on August 31, 2002.

(a) Reflects the accounting for the merger of Quantum HIPAA Consulting Group, Inc., which consists of issuance of 27,000,000 shares of common stock and the cancellation of 7,000,000 for the disposition of the operating subsidiary as per the merger agreement.

(b) Reflects assumption of 112,036 of the registrant's payables and 8,816 of merger related expenses

16